The Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency met on 13-15 January 2026 and adopted a positive opinion on the authorization of Elanco's Lotilaner/Milbemycin for dogs[1]. The drug is intended for the treatment and prevention of mixed parasitic infections including ticks, fleas, mites, intestinal nematodes, heartworm and lungworm[1]. Lotilaner is an isoxazoline active substance that acts as an inhibitor of GABA-gated chloride channels, resulting in the rapid death of ticks and fleas[2]. The drug provides efficacy lasting one month and has a terminal half-life of approximately four weeks, ensuring effective blood levels throughout the interval between doses[2]. The main route of excretion is biliary excretion, while renal excretion represents less than 10% of the dose[2]. No interactions with commonly used veterinary drugs were observed during clinical trials[2]. In preclinical studies, no adverse effects were observed even at high doses of up to five times the recommended dose[2].